Alzamend Neuro, Inc. (ALZN)

2.1300 -0.0700 (-3.18%) As of 04:00PM EST. Market open.

Alzamend Neuro, Inc.

3802 Spectrum Boulevard
Suite 112C
Tampa, FL 33612
United States
844 722 6333
http://www.alzamend.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Stephan Jackman	CEO & Director	225k	N/A	1976
Mr. Henry C.W. Nisser Esq.	Exec. VP, Gen. Counsel & Director	50k	N/A	1969
Mr. Kenneth S. Cragun CPA	Sr. VP of Fin.	100k	N/A	1961
Mr. Milton Charles Ault III	Founder & Chairman Emeritus	N/A	N/A	1970
Ms. Lien T. Escalona	Chief Financial Officer	N/A	N/A	1969
Mr. David J. Katzoff	Chief Operating Officer	N/A	N/A	1962

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.

Corporate governance

Alzamend Neuro, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.